Is Johnson & Johnson (JNJ) overvalued or fairly valued?

MarketChacha shows Johnson & Johnson's valuation in context — a trailing P/E of about 29.7, a forward P/E of about 21.3, a price-to-book of about 7.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Johnson & Johnson's reported profit turn into cash?

Over 3 years, about 94% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement. MarketChacha computes this cash-conversion check (0.94×) from reported figures — education, not a rating.

What is Johnson & Johnson's revenue?

Johnson & Johnson reported revenue of $94.2B for FY2025, with net profit of $26.8B, per official filings.

What is the share price of Johnson & Johnson (JNJ)?

Johnson & Johnson last traded at $261.81 (+1.0% on the day), as of 8/10/2026 — a delayed quote shown for education, not investment advice.

Johnson & Johnson

JNJ · NYSE · Healthcare · United States

Snapshot

TickerJNJ

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUnited States

Employees138,200

HeadquartersNew Brunswick, United States

Websitewww.jnj.com

Filings tracked13

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Who owns it

Insiders0.1%
Institutions77.0%
Public & other23.0%

5,767 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.80%
Vanguard Capital Management LLC6.50%
State Street Corporation5.55%
Vanguard Portfolio Management LLC2.64%
JPMORGAN CHASE & CO2.62%
Geode Capital Management, LLC2.46%
Morgan Stanley1.86%
State Farm Mutual Automobile Insurance Co1.31%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years, about 94% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement.

Cash conversion0.94×

Over 3 years, about 94% of reported profit turned into operating cash — most of it, but worth reading alongside the cash-flow statement.

Net margin trend41.3% → 28.5%

Margin has compressed by about 12.8 points over the period — profitability is trending down.

Return on equity32.9%

Latest ROE of 32.9% — capital is generating a healthy return.

Growth qualityrev 5% · PAT -13%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $26.6B · EPS 3.02

Est. earnings growth +23.0%

Next fiscal year

Rev $108.8B · EPS 12.31

Est. earnings growth +11.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$94.2B

Net margin

28.5%

ROE

32.9%

Revenue CAGR (2y)

+5.2%

Profit CAGR (2y)

-12.7%

EPS (FY2025)

11.03

Net profit (FY2025)

$26.8B

Ask MarketChacha about JNJ

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$94.2B	$26.8B	11.03	28.5%	32.9%
FY2024	$88.8B	$14.1B	5.79	15.8%	19.7%
FY2023	$85.2B	$35.2B	13.72	41.3%	45.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$25.3B	$5.5B	2.27	21.9%
2026Q1	$24.1B	$5.2B	2.14	21.8%
2025Q3	$24.0B	$5.2B	2.12	21.5%
2025Q2	$23.7B	$5.5B	2.29	23.3%
2025Q1	$21.9B	$11.0B	4.54	50.2%
2024Q3	$22.5B	$2.7B	1.11	12.0%
2024Q2	$22.4B	$4.7B	1.93	20.9%
2024Q1	$21.4B	$3.3B	1.34	15.2%
2023Q4	$21.4B	$26.0B*	10.21	—
2023Q3	$21.5B	$5.1B	1.96	23.9%
2023Q2	$20.9B	$-68.0M	-0.03	-0.3%
2023Q1	$19.9B	$3.5B	1.33	17.7%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Exhibits
SEC8/4/2026material
8-K — Reg FD disclosure, Exhibits
SEC7/29/2026material
8-K — Reg FD disclosure, Exhibits
SEC7/28/2026material
10-Q filing
SEC7/23/2026
8-K — Results of operations, Exhibits
SEC7/15/2026material
8-K — Shareholder vote results, Exhibits
SEC4/28/2026material
10-Q filing
SEC4/22/2026
8-K — Results of operations, Other events, Exhibits
SEC4/14/2026material
10-K filing
SEC2/11/2026
8-K — Results of operations, Exhibits
SEC1/21/2026material

2025

10-Q filing
SEC10/22/2025
8-K — Results of operations, Other events, Exhibits
SEC10/14/2025material
8-K — Executive/director change
SEC9/9/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.